The gene expression patterns of BMPR2, EP300, TGFβ2, and TNFAIP3 in B-Lymphoma cells

Cancer Biology and Medicine

Volumn 11, Issue 3, 2014, Pages 202-207

  He, Dong Mei ^a   Wu, Hong ^a   Wu, Xiu Li ^a   Ding, Li ^a   Xu, Ling ^a   Li, Yang Qiu ^a,b  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

Author keywords

B lymphoma cells; Bone morphogenetic protein receptor, type II (BMPR2); E1A binding protein p300 (EP300); factor 2 (TGF 2); Myeloid leukemia cells; Quantitative reverse transcription polymerase chain reaction (qRT PCR); Transforming growth; Tumor necrosis factor, and alpha induced protein 3 (TNFAIP3)

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; DYE; E1A ASSOCIATED P300 PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR AND ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B CELL LYMPHOMA; B-CELL LYMPHOMA CELL LINE; BONE MARROW CULTURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; MALE; MIDDLE AGED; MYELOID LEUKEMIA; MYELOID LEUKEMIA CELL LINE; NORMAL HUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84908092004     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2014.03.006     Document Type: Article

References (25)

1. Deffenbacher KE, Iqbal J, Sanger W, Shen Y, Lachel C, Liu Z, et al. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood 2012; 119: 3757-3766.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
3. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003; 8: 541-552.
4. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
5. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
6. Bellan C, Stefano L, Giulia de F, Rogena EA, Lorenzo L. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach. Hematol Oncol 2010; 28: 53-56.
7. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354: 2431-2442.
8. Satterwhite E, Sonoki T, Willis TG, Harder L, Nowak R, Arriola EL, et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood 2001; 98: 3413-3420.
9. Liu H, Ippolito GC, Wall JK, Niu T, Probst L, Lee BS, et al. Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells. Mol Cancer 2006; 5: 18.
10. Yin B, Delwel R, Valk PJ, Wallace MR, Loh ML, Shannon KM, et al. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. Blood 2009; 113: 1075-1085.
11. Gao Y, He D, Chen S, Yan X, Hu X, Li Y. Expression of the B-cell lymphoma/leukemia 11A gene in malignant hematological cell lines through quantitative reverse transcription polymerase chain reaction. Clin Oncol Cancer Res 2011; 8: 242-246.
12. Dzietczenia J, Wróbel T, Jaźwiec B, Mazur G, Butrym A, Poręba R, et al. Expression of bone morphogenetic proteins (BMPs) receptors in patients with B-cell chronic lymphocytic leukemia (B-CLL). Int J Lab Hematol 2010; 32: e217-221.
13. Owens P, Pickup MW, Novitskiy SV, Chytil A, Gorska AE, Aakre ME, et al. Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proc Natl Acad Sci U S A 2012; 109: 2814-2819.
14. Grcević D, Marusić A, Grahovac B, Jaksić B, Kusec R. Expression of bone morphogenetic proteins in acute promyelocytic leukemia before and after combined all trans-retinoic acid and cytotoxic treatment. Leuk Res 2003; 27: 731-738.
15. Garbati MR, Alço G, Gilmore TD. Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RCK8. Cancer Lett 2010; 291: 237-245.
16. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004; 23: 4225-4231.
17. Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009; 114: 2467-2475.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
19. Papakonstantinou G, Verbeke C, Hastka J, Bohrer M, Hehlmann R. bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements. Br J Haematol 2001; 113: 383-390.
20. Lin HK, Bergmann S, Pandolfi PP. Deregulated TGF-beta signaling in leukemogenesis. Oncogene 2005; 24: 5693-5700.
21. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010; 10: 415-424.
22. Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 1994; 179: 999-1004.
23. Ho CL, Sheu LF, Li CY. Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non-Hodgkin lymphoma. Ann Diagn Pathol 2003; 7: 1-8.
24. Paik JH, Go H, Nam SJ, Kim TM, Heo DS, Kim CW, et al. Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment. Leuk Lymphoma 2013; 54: 1934-1941.
25. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471: 189-195.